HIGHLIGHTS
- who: Britt E. Heidemann MD from the Department of Vascular Medicine, University Medical Center Utrecht, Utrecht University, The Netherlands have published the Article: Effect of evolocumab on fasting and post fat load lipids and lipoproteins in familial dysbetalipoproteinemia, in the Journal: (JOURNAL) of November/13,/2022
- what: This study was designed to investigate whether the effect of PCSK9 mAbs would be similar in FD patients, since they generally have low LDL-C levels and TRLs with dysfunctional apoE that does not bind to the LDL-R. The aim of the EVOLVE-FD (Effects of EVOLocumab . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.